JP2013500711A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500711A5
JP2013500711A5 JP2012522191A JP2012522191A JP2013500711A5 JP 2013500711 A5 JP2013500711 A5 JP 2013500711A5 JP 2012522191 A JP2012522191 A JP 2012522191A JP 2012522191 A JP2012522191 A JP 2012522191A JP 2013500711 A5 JP2013500711 A5 JP 2013500711A5
Authority
JP
Japan
Prior art keywords
protein
adamts13
buffer
adamts13 protein
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012522191A
Other languages
English (en)
Japanese (ja)
Other versions
JP5907869B2 (ja
JP2013500711A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/061192 external-priority patent/WO2011012726A2/en
Publication of JP2013500711A publication Critical patent/JP2013500711A/ja
Publication of JP2013500711A5 publication Critical patent/JP2013500711A5/ja
Application granted granted Critical
Publication of JP5907869B2 publication Critical patent/JP5907869B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012522191A 2009-07-31 2010-08-02 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物 Active JP5907869B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
US61/230,308 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015105808A Division JP6216930B2 (ja) 2009-07-31 2015-05-25 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物

Publications (3)

Publication Number Publication Date
JP2013500711A JP2013500711A (ja) 2013-01-10
JP2013500711A5 true JP2013500711A5 (enExample) 2013-09-12
JP5907869B2 JP5907869B2 (ja) 2016-04-26

Family

ID=42588355

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012522191A Active JP5907869B2 (ja) 2009-07-31 2010-08-02 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2015105808A Active JP6216930B2 (ja) 2009-07-31 2015-05-25 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2016194640A Withdrawn JP2016222724A (ja) 2009-07-31 2016-09-30 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2018188301A Withdrawn JP2018203781A (ja) 2009-07-31 2018-10-03 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2020174837A Pending JP2021004265A (ja) 2009-07-31 2020-10-16 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2022150048A Pending JP2022171925A (ja) 2009-07-31 2022-09-21 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015105808A Active JP6216930B2 (ja) 2009-07-31 2015-05-25 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2016194640A Withdrawn JP2016222724A (ja) 2009-07-31 2016-09-30 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2018188301A Withdrawn JP2018203781A (ja) 2009-07-31 2018-10-03 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2020174837A Pending JP2021004265A (ja) 2009-07-31 2020-10-16 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
JP2022150048A Pending JP2022171925A (ja) 2009-07-31 2022-09-21 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物

Country Status (22)

Country Link
US (3) US8945895B2 (enExample)
EP (3) EP3211077B1 (enExample)
JP (6) JP5907869B2 (enExample)
KR (7) KR101769634B1 (enExample)
CN (3) CN102482660A (enExample)
AU (1) AU2010277491B2 (enExample)
CA (2) CA2769362A1 (enExample)
CO (1) CO6612194A2 (enExample)
DK (1) DK2459715T3 (enExample)
EA (3) EA201992487A1 (enExample)
ES (3) ES3039686T3 (enExample)
HR (1) HRP20192303T1 (enExample)
HU (1) HUE046909T2 (enExample)
IN (1) IN2012DN00907A (enExample)
LT (1) LT2459715T (enExample)
MX (2) MX2012001263A (enExample)
NZ (2) NZ597756A (enExample)
PL (2) PL2459715T3 (enExample)
PT (1) PT2459715T (enExample)
SG (2) SG178175A1 (enExample)
SI (1) SI2459715T1 (enExample)
WO (1) WO2011012726A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
DK2686335T3 (en) * 2011-03-14 2018-07-30 Catalant Pharma Solutions Llc DECORINE COMPOSITIONS AND APPLICATION THEREOF
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2829968T3 (es) * 2012-06-21 2021-06-02 Takeda Pharmaceuticals Co Filtración de virus de medios de cultivo celular
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014110246A1 (en) * 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
KR102537083B1 (ko) 2016-08-04 2023-05-25 다케다 파머수티컬 컴패니 리미티드 겸상적혈구병, 급성 폐 손상 및/또는 급성 호흡 곤란 증후군에서 혈관폐색 위기의 치료, 개선, 및/또는 예방을 위한 adamts13의 용도
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN112105430A (zh) * 2018-04-03 2020-12-18 默克专利股份有限公司 Cex色谱介质和生物药物进料中目标蛋白的低盐洗脱
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
EP3947705A1 (en) * 2019-04-03 2022-02-09 Genzyme Corporation Continuous production of recombinant proteins
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
EP4408876A1 (en) * 2021-09-30 2024-08-07 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
AU2023230335A1 (en) 2022-03-07 2024-08-29 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
TW202400238A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 血漿蛋白之新穎液體調配物
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample
WO2025224621A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69329108T2 (de) 1992-03-02 2001-03-22 Bioeng, Inc. Verfahren zur inaktivierung von viren
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
JPWO2002031163A1 (ja) * 2000-10-11 2004-02-19 財団法人かずさディー・エヌ・エー研究所 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
AU2002336367A1 (en) 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
EP1470160A2 (en) * 2001-12-05 2004-10-27 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
JP4363986B2 (ja) 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP3944586B2 (ja) * 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
DE602004029058D1 (de) 2003-07-09 2010-10-21 Shinonogi & Co Ltd Inducer von atopischer dermatitis
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US20080138790A1 (en) * 2004-04-13 2008-06-12 Winslow Robert M Methods and Compositions for Simultaneously Isolating Hemoglobin from Red Blood Cells and Inactivating Viruses
DK1765866T3 (en) 2004-06-07 2014-03-24 Therapure Biopharma Inc ISOLATION OF plasma or serum protein
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
WO2006072579A1 (en) * 2005-01-05 2006-07-13 Foundation For Fatal Rare Disease Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
AU2006257073B2 (en) 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
EP1990421B1 (en) 2006-02-16 2012-06-13 Mitsubishi Chemical Medience Corporation Method of detecting condition in patient with disturbance of consciousness
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
US8669045B2 (en) 2007-02-13 2014-03-11 Ajinomoto Co., Inc. Method for inactivating viruses with slightly acidic arginine
US8685665B2 (en) 2007-06-22 2014-04-01 The Chemo-Sero-Therapeutic Research Institute ADAMTS-13 mutant
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
DE602008005885D1 (de) 2007-07-11 2011-05-12 Novo Nordisk As Aufreinigung von faktor viii unter verwendung eine
EP2197421A1 (en) * 2007-08-31 2010-06-23 Amgen, Inc Solid-state protein formulation
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Similar Documents

Publication Publication Date Title
JP2013500711A5 (enExample)
HRP20192303T1 (hr) Postupak za pročišćavanje rekombinantnog adamts13 i drugih proteina i njihovih pripravaka
RU2015141849A (ru) Способ очистки фактора свертывания крови viii
JP2011510303A5 (enExample)
EP0443724B1 (en) Viral-safe purified human thrombin
JP6720288B2 (ja) ウイルス用無菌精製プロセス
AU2015203388B2 (en) Process for purifying vitamin K dependent proteins
JP2011525523A5 (enExample)
JPS61275210A (ja) ウイルス及び発熱原不活性化剤を用いる固相に吸着させた生物医学的生成物及び製薬生成物の処理法
JPS5944320A (ja) Ｃ１不活性化剤の調製方法
CN105566489B (zh) 一种制备不同铁饱和度乳铁蛋白的方法
CA2340863A1 (en) Thrombin preparations and process for their production
CN102234332B (zh) 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
CN103534264B (zh) 血栓形成试剂减少的免疫球蛋白及其制备
ES2743711T3 (es) Un proceso para la reducción y/o retirada de FXI y FXIa de soluciones que contienen fichos factores de coagulación
JP2007523883A5 (enExample)
US20130164821A1 (en) Method for separating viruses from a contaminant-containing liquid
KR100320394B1 (ko) 멤브레인크로마토그래피시켜비타민-k의존형단백질을정제시키는방법
JP2014518508A5 (enExample)
JP5137491B2 (ja) 水酸化アルミニウム吸着体の吸着性及び／又は溶出性の改変方法
JP2009039038A (ja) 被分離物質の分離方法及び精製方法
UA43855C2 (uk) Спосіб одержання вірусоінактивованої фракції, що містить фактор yiii, та фракція, що містить фактор yiii
CN1798573A (zh) 白蛋白溶液及其制备方法
AU739845B2 (en) A method for inactivating pathogens, in particular viruses, in a biological material
JP2009042074A (ja) 吸着担体及び吸着担体の製造方法